Capecitabine Treatment: A Safe and Effective Therapy in the Field of Oncology
- 10 April 2021
- journal article
- letter
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 20 (3), e194-E194
- https://doi.org/10.1016/j.clcc.2021.04.003
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients with Metastatic Colorectal Cancer: A Retrospective ReviewClinical Colorectal Cancer, 2020
- Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of conceptScientific Reports, 2018
- Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuationZeitschrift für Krebsforschung und Klinische Onkologie, 2017
- A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver functionClinical and Molecular Hepatology, 2017
- Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosisThe Lancet Oncology, 2017
- Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failureDigestive and Liver Disease, 2015
- Metronomic Capecitabine in Patients With Hepatocellular Carcinoma Unresponsive to or Ineligible for Sorafenib Treatment: Report of Two CasesHepatitis Monthly, 2013